In this randomized trial involving infertile women with the polycystic ovary syndrome, frozen-embryo transfer was associated with a higher rate of live birth than was fresh-embryo transfer after the ...first transfer.
In vitro fertilization (IVF) is widely performed as an infertility treatment and has resulted in the births of more than 5 million infants worldwide.
1
However, there are concerns about the safety of the procedures for women and for their infants.
1
,
2
The ovarian hyperstimulation syndrome (which is caused by ovarian enlargement, an increase in vascular permeability and abdominal ascites, and intravascular hemoconcentration) is a potentially life-threatening complication of ovarian stimulation.
3
Pregnancies conceived by means of IVF are associated with greater risks of maternal and neonatal complications, including preeclampsia, preterm delivery, low birth weight, and congenital anomalies, than are spontaneous pregnancies. . . .
New sets of parameters (“tunes”) for the underlying-event (UE) modelling of the
pythia
8,
pythia6
and
herwig++
Monte Carlo event generators are constructed using different parton distribution ...functions. Combined fits to CMS UE proton–proton (
p
p
) data at
s
=
7
TeV
and to UE proton–antiproton (
p
p
¯
) data from the CDF experiment at lower
s
, are used to study the UE models and constrain their parameters, providing thereby improved predictions for proton–proton collisions at 13
TeV
. In addition, it is investigated whether the values of the parameters obtained from fits to UE observables are consistent with the values determined from fitting observables sensitive to double-parton scattering processes. Finally, comparisons are presented of the UE tunes to “minimum bias” (MB) events, multijet, and Drell–Yan (
q
q
¯
→
Z
/
γ
∗
→
lepton-antilepton+jets) observables at 7 and 8
TeV
, as well as predictions for MB and UE observables at 13
TeV
.
Celotno besedilo
Dostopno za:
DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early clinical experience with a novel class I RAF-selective inhibitor, ...PLX4032, demonstrated an unprecedented 80% anti-tumour response rate among patients with B-RAF(V600E)-positive melanomas, but acquired drug resistance frequently develops after initial responses. Hypotheses for mechanisms of acquired resistance to B-RAF inhibition include secondary mutations in B-RAF(V600E), MAPK reactivation, and activation of alternative survival pathways. Here we show that acquired resistance to PLX4032 develops by mutually exclusive PDGFR (also known as PDGFRB) upregulation or N-RAS (also known as NRAS) mutations but not through secondary mutations in B-RAF(V600E). We used PLX4032-resistant sub-lines artificially derived from B-RAF(V600E)-positive melanoma cell lines and validated key findings in PLX4032-resistant tumours and tumour-matched, short-term cultures from clinical trial patients. Induction of PDGFR RNA, protein and tyrosine phosphorylation emerged as a dominant feature of acquired PLX4032 resistance in a subset of melanoma sub-lines, patient-derived biopsies and short-term cultures. PDGFR -upregulated tumour cells have low activated RAS levels and, when treated with PLX4032, do not reactivate the MAPK pathway significantly. In another subset, high levels of activated N-RAS resulting from mutations lead to significant MAPK pathway reactivation upon PLX4032 treatment. Knockdown of PDGFR or N-RAS reduced growth of the respective PLX4032-resistant subsets. Overexpression of PDGFR or N-RAS(Q61K) conferred PLX4032 resistance to PLX4032-sensitive parental cell lines. Importantly, MAPK reactivation predicts MEK inhibitor sensitivity. Thus, melanomas escape B-RAF(V600E) targeting not through secondary B-RAF(V600E) mutations but via receptor tyrosine kinase (RTK)-mediated activation of alternative survival pathway(s) or activated RAS-mediated reactivation of the MAPK pathway, suggesting additional therapeutic strategies.
Celotno besedilo
Dostopno za:
DOBA, IJS, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
PDF
